
Conference Coverage
Latest Content

Ultraprocessed Foods Linked to Higher Risk of Early-Onset Colorectal Adenomas

Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care

Clinician Shortages, Access Gaps Challenge Rural Primary Care

Guselkumab Shows Sustained 48-Week Protection Against Joint Damage in PsA

NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Cuts to Medicaid could spell trouble for pediatric health, as millions of children rely on Medicaid to cover their hospital expenses.

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

The race of a telephonic care manager did not impact closure rates for gaps in care among Black Medicare Advantage beneficiaries.

Patients 65 years and older had improved overall and cancer-specific survival after undergoing chemoradiotherapy for stage 2 NSCLC.

Topline results find that single-tablet regimen of bictegravir/lenacapavir had noninferior efficacy when patients switched from multitablet regimens in HIV.

A novel RTEL1 nonsense mutation was identified in a woman with multigenerational familial pulmonary fibrosis (PF), expanding the genetic spectrum of telomere-related lung disease and underscoring the importance of genetic testing in suspected inherited interstitial lung disease (ILD).

A wide range of non-invasive tests reliably reflected semaglutide-related improvements in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

Routine flow cytometry can reliably track chimeric antigen receptor (CAR) T-cell expansion and persistence in aggressive large B-cell lymphoma (LBCL).

Immunoglobulin heavy chain variable is an important prognostic biomarker in chronic lymphocytic leukemia, but the authors of a new review say its role has yet to be fully understood.

The causes of financial hardship among people with rheumatoid arthritis are not necessarily based on the cost of disease-modifying therapies, according to new research.






























































